How immune system patterns relate to control of inflammatory airway diseases
Studies blood immune cells in adults with asthma, COPD, bronchiectasis and related airway diseases.
Plain-language title generated from the registry record
Registry title: Immune Status and Disease Control of Inflammatory Airway Diseases
Key facts
- Where
- Ningbo, ChinaSee the site
Where in China
- The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Ningbo University
- Trial code
- NCT07493629
- Record updated
- 25 March 2026
- Original description
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:Read full original descriptionShow less
Association Between Immune Status and Disease Control in Patients With Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand:
1.Whether specific immune cell patterns in the blood are linked to how severe the disease is or how well it is controlled.
Participants will:
1. Answer questions about their health and symptoms. 2. Give blood samples 3. Have lung function tests and other standard check-ups. 4. share sleep study results. We will compare people with airway diseases to healthy volunteers to see how their immune systems differ.
Inclusion: Age ≥18 years (≥40 years for COPD patients); Clinical diagnosis of asthma, ABPA, bronchiectasis, OSAS, or COPD according to established criteria; PRISm patients (post-BD FEV1/FVC ≥70% and FEV1 <80% predicted); Smoking controls: ≥10 pack-years, normal lung function, no chronic respiratory symptoms; Healthy controls: normal lung function, FeNO <20 ppb, total IgE <100 IU/mL, no chronic disease, smoking <10 pack-years, no immunosuppressant use within 3 months.
Exclusion: Patients with an acute exacerbation within 4 weeks before enrollment, or systemic use of antibiotics, antifungal drugs, immunosuppressive agents, cytotoxic agents, or corticosteroids (except for long-term maintenance therapy); Patients with severe respiratory diseases other than those included in the study, such as pulmonary embolism, pneumothorax, pulmonary hypertension, interstitial lung disease, or active lung cancer; Patients with severe systemic diseases that may interfere with study completion, such as myocardial infarction, severe arrhythmia, hepatic insufficiency, renal insufficiency, hematological disorders, or malignancy; Pregnant or lactating women; Patients with poor compliance as judged by the investigators; Subjects currently participating in other clinical studies.